Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVAX-1107 and UVAX-1197 HIV-1 Vaccine Study in Healthy Adults
NCT06541093Phase 1Completed
- Sponsor
- Uvax Bio
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of UVAX-1107 and UVAX-1197 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Uvax Bio. Primary endpoints: Local and Systemic Reactogenicity and Anti-HIV-1 Protein IgG Response at Day 337. Started Jan 2024; status: completed.
02
Drugs
UVAX-1107UVAX-1197
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06541093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541093.